Black Rock Inc. Cytosorbents Corp Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Cytosorbents Corp stock. As of the latest transaction made, Black Rock Inc. holds 722,435 shares of CTSO stock, worth $621,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares

722,435

Previous 726,320 0.53%

Holding current value

$621,294

Previous $806,000 14.89%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.86 - $1.07 $3,341 - $4,156	-3,885 Reduced 0.53%	722,435 $686,000
Q4 2023 Feb 13, 2024	SELL	$1.08 - $1.94 $479 - $861	-444 Reduced 0.06%	726,320 $806,000
Q3 2023 Nov 13, 2023	SELL	$1.86 - $4.03 $61,839 - $133,985	-33,247 Reduced 4.37%	726,764 $1.37 Million
Q2 2023 Aug 11, 2023	BUY	$2.37 - $3.65 $35,803 - $55,140	15,107 Added 2.03%	760,011 $2.73 Million
Q1 2023 May 12, 2023	BUY	$1.79 - $4.17 $5,096 - $11,871	2,847 Added 0.38%	744,904 $2.51 Million

Q4 2022 Feb 13, 2023	BUY	$1.03 - $1.63 $706 - $1,118	686 Added 0.09%	742,057 $1.15 Million
Q3 2022 Nov 14, 2022	SELL	$1.39 - $2.46 $4,985 - $8,824	-3,587 Reduced 0.48%	741,371 $1.01 Million
Q2 2022 Aug 12, 2022	SELL	$1.76 - $3.22 $3.27 Million - $5.97 Million	-1,855,479 Reduced 71.35%	744,958 $1.63 Million
Q1 2022 May 12, 2022	SELL	$2.88 - $4.23 $88,626 - $130,169	-30,773 Reduced 1.17%	2,600,437 $8.3 Million
Q4 2021 Feb 10, 2022	BUY	$4.05 - $8.11 $293,292 - $587,309	72,418 Added 2.83%	2,631,210 $11 Million
Q3 2021 Nov 09, 2021	SELL	$7.0 - $9.71 $576,618 - $799,851	-82,374 Reduced 3.12%	2,558,792 $20.8 Million
Q2 2021 Aug 11, 2021	BUY	$7.55 - $9.42 $19.9 Million - $24.9 Million	2,641,166 New	2,641,166 $19.9 Million

Others Institutions Holding CTSO

# of Institutions

Shares Held

17.8M

Call Options Held

Put Options Held

View Full List

About Cytosorbents Corp

Ticker CTSO
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 43,577,400
Market Cap $37.5M
Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...

More about CTSO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account